Disparities in Guideline Concordant Treatment for Pathologic N1 Non-Small Cell Lung Cancer

Publication date: Available online 24 January 2020Source: The Annals of Thoracic SurgeryAuthor(s): Omar Toubat, Scott M. Atay, Anthony W. Kim, Li Ding, Albert J. Farias, Peggy J. Ebner, P. Michael McFadden, Elizabeth A. DavidAbstractBackgroundSocioeconomic status (SES) disparities in the surgical management of patients with non-small cell lung cancer (NSCLC) are well-described. Disparities in the receipt of adjuvant chemotherapy are poorly understood. We assessed the influence of SES on adjuvant chemotherapy following resection in patients with pN1 NSCLC.MethodsThe National Cancer Database was queried for cN0/N1 NSCLC patients who underwent surgical resection and had demonstrated pN1 disease. This cohort was further divided into those who received multi-agent adjuvant chemotherapy (MAAC) versus surgery only treatment. Factors associated with treatment assignment were examined and long-term survival was compared.ResultsOf the 14,892 patients who underwent resection for pN1 disease, 8,061 (54.1%) received MAAC. Patients were less likely to receive MAAC if they resided in rural areas (OR 1.23, 95% CI 1.11-1.37, p
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research

Related Links:

ConclusionsAntiangiogenic agents can achieve therapeutic benefit in advanced NSCLC patients and the combination of chemotherapy, targeted therapy or immunotherapy can lead to synergistic effect. However, exploring the best combination therapy and efficacy-related biomarkers needs further study.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsPrior to the approval of durvalumab, the clinical application of ICIs improved the outcome of patients with relapsed NSCLC after CRT for LA ‐NSCLC. The management of radiation pneumonitis remains a challenge following the approval of durvalumab.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsThe recommended doses for this combination therapy are carboplatin AUC 5 and S-1 80  mg/m2/day every 3  weeks, and this combination is effective with tolerable toxicities for advanced NSCLC patients ≥ 75 years old.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
In this study, we attempted to fabricate Nitroimidazoles (NI) and Hyaluronic acid (HA) co-decorated, cisplatin (DDP) loaded polymeric nanoparticles (PNPs) (NI/HA-DDP-PNPs) and lipid-polymer hybrid nanoparticles (LPNs) (NI/HA-DDP-LPNs) for the facilitated drug delivery at lung tumor regions (hypoxic regions). In vitro cytotoxicity and cellular uptake; In vivo anti-tumor activity and in vivo tissue biodistribution of PNPs and LPNs were evaluated and compared in lung carcinoma cells and xenograft. Hydrodynamic size of NI/HA-DDP-LPNs was 185.6 ± 4.7 nm, which is larger than that of NI/HA-DDP-PNPs (136.7 ± 3.5 nm)...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Conditions:   Lung Non-Small Cell Carcinoma;   Stage IB Lung Cancer AJCC v7;   Stage II Lung Cancer AJCC v7;   Stage IIA Lung Cancer AJCC v7;   Stage IIB Lung Cancer AJCC v7;   Stage IIIA Lung Cancer AJCC v7 Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Other: Observation;   Drug: Paclitaxel;   Biological: Pembrolizu...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In conclusion, this work might provide beneficial evidence of KLTi combined with chemotherapy for improving clinical efficacy and immune function, as well as reducing the incidence of adverse events in advanced NSCLC patients. KLTi might be a beneficial therapeutic method for the treatment of advanced NSCLC. Due to the quality of the data, more rigorous and well-designed RCTs are needed to confirm these findings. PMID: 32047528 [PubMed]
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
AbstractIntroductionThe aim of the study was to extract anthropometric measures from CT by deep learning and to evaluate their prognostic value in patients with non-small-cell lung cancer (NSCLC).MethodsA convolutional neural network was trained to perform automatic segmentation of subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and muscular body mass (MBM) from low-dose CT images in 189 patients with NSCLC who underwent pretherapy PET/CT. After a fivefold cross-validation in a subset of 35 patients, anthropometric measures extracted by deep learning were normalized to the body surface area (BSA) to contr...
Source: European Radiology - Category: Radiology Source Type: research
llo I Abstract Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death mainly due to its high metastatic rate. Impairment of redox homeostasis mechanisms has been previously described in NSCLC and is associated with the disease itself as well as with comorbidities such as smoking. The aim of the present in vitro study was to evaluate the effect of selective and non-competitive inhibition of heme oxygenase-1 (HO-1) on cancer redox homeostasis with particular regards to glutathione (GSH) metabolism related enzymes. NSCLC cell line (A549) was treated with the HO-1 activity inhibitor VP13/...
Source: Molecular Biology Reports - Category: Molecular Biology Authors: Tags: Mol Biol Rep Source Type: research
The U.S. Food and Drug Administration has granted final approval of Pemfexy, a new brand of the chemotherapy drug pemetrexed, to combat malignant mesothelioma and advanced stage non-small cell lung cancer. The approval will allow oncologists to offer an alternative to Alimta, which today is considered standard pemetrexed and manufactured by Eli Lilly and Company. The chemotherapy drug is designed to block DNA replication and cell division. However, Pemfexy will not be available until February 2022. The FDA approval is limited to pleural mesothelioma patients whose disease is unresectable. Pemfexy is produced by Eagle Pharm...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Condition:   Non-small Cell Lung Cancer (NSCLC) Interventions:   Drug: Atezolizumab;   Drug: RO7198457 Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Databases & Libraries | Insurance | Lung Cancer | Medicaid | Non-Small Cell Lung Cancer | Rural Health | Uninsured